NICARDIPINE ANTI-ANGINA NDA NEEDS FURTHER DATA, FDA CMTE. TELLS SYNTEX
Nicardipine's anti-anginal efficacy must be established beyond four hours before the calcium channel blocker can be considered for approval, FDA's Cardiorenal Drugs Advisory Committee unanimously agreed at its September 30 meeting. Committee Chairman Jeffrey Borer, MD, Cornell Medical Center said the committee cannot recommend approval of nicardipine for treatment of angina "because there are data missing." The committee agreed that the syntex had established a relationship between dose and peak effect. However, the committee felt the company had not established a relationship between dose and duration of effect. "There is a big hole between four and eight hours in the data," committee member Carl Leier, MD, Ohio State University Medical School, stated. FDA Cardio-Renal Drug Division Director Raymond Lipicky, MD, concurred: "I don't disagree at all that one was able to distinguish nicardipine from placebo, but as best as one can tell from the data, that efficacy lasts for four hours." Another problem centered on the committee's perception that the Syntex studies did not show a mechanism of action for nicardipine. "These data are interesting," Borer stated, "but I don't think they define a mechanism for preventing ischemia on the basis of improved myocardial profusion." Borer continued: "You haven't demonstrated the mechanism that you suggested in this data and therefore there are certain conclusions that we might want to make about how this drug could be used but we can't." Syntex filed a nicardipine NDA for angina in 1985, and said it plans to file an NDA for hypertension before the end of 1986. Licensed from the Japanese firm Yamanouchi, the calcium channel blocker will be marketed under the brand name Cardene. Syntex has sublicensing agreements for injectable and long-acting forms of the drug with American Critical Care (DuPont) and Key (Schering-Plough) respectively.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth